本文言語 | English |
---|---|
ページ(範囲) | 886-887 |
ページ数 | 2 |
ジャーナル | Annals of Surgical Oncology |
巻 | 27 |
DOI |
|
出版ステータス | Published - 2020 12月 |
ASJC Scopus subject areas
- 外科
- 腫瘍学
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Surgical Oncology, Vol. 27, 12.2020, p. 886-887.
研究成果: Comment/debate › 査読
}
TY - JOUR
T1 - ASO Author Reflections
T2 - Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients
AU - Matsuda, Satoru
AU - Takeuchi, Hiroya
AU - Kawakubo, Hirofumi
AU - Takemura, Ryo
AU - Maeda, Yusuke
AU - Hirata, Yuki
AU - Kaburagi, Takuji
AU - Egawa, Tomohisa
AU - Nishi, Tomohiko
AU - Ogura, Masaharu
AU - Miyasho, Taku
AU - Okamura, Akihiko
AU - Mayanagi, Shuhei
AU - Fukuda, Kazumasa
AU - Nakamura, Rieko
AU - Irino, Tomoyuki
AU - Wada, Norihito
AU - Kitagawa, Yuko
N1 - Funding Information: Yuko Kitagawa: Relevant financial activities outside the submitted work: Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd, Daiichi Sankyo Company, Ltd, Merck Serono Co., Ltd, Asahikasei Co., Ltd, EA Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd, Kaken Pharmaceutical Co., Ltd, Kowa Pharmaceutical Co., Ltd, Astellas Pharma Inc., Medicon Inc., Dainippon Sumitomo Pharma Co., Ltd, Taisho Toyama Pharmaceutical Co., Ltd, Kyouwa Hakkou Kirin Co., Ltd, Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd, Nihon Pharmaceutical Co., Ltd, Japan Blood Products Organization Medtronic Japan Co., Ltd, Sanofi KK. Yuko Kitagawa received grants from Eisai Co., Ltd, Tsumura & Co., KCI Licensing, Inc., Abbott Japan Co., Ltd, and Fujifilm Toyama Chemical Co., Ltd.
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85089090093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089090093&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-09008-1
DO - 10.1245/s10434-020-09008-1
M3 - Comment/debate
C2 - 32761333
AN - SCOPUS:85089090093
SN - 1068-9265
VL - 27
SP - 886
EP - 887
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
ER -